Women who use certain types of hormone replacement therapy (HRT) are at a higher risk of developing potentially life-threatening blood clots, new research has confirmed.
The study, undertaken by researchers at The University of Nottingham and published in the BMJ, found that the risk of developing blood clots was only increased for women using HRT in tablet form and was slightly higher for higher dosages.
The experts hope the results will help to provide clearer, detailed information for patients and doctors about the relative risks of blood clots for all HRT treatments and enable them to make good treatment choices.
Hormone replacement therapy (HRT) is used to relieve symptoms such as hot flushes and night sweats and reduce the risk of certain health conditions in women going through the menopause.
There are a range of different HRT treatments available, depending on the symptoms experienced. Some women require a drug based only on the oestrogen hormone, while others may need a combination of oestrogen and another hormone, progesterone. HRT can also be taken in different forms – by tablets, patches, gels or creams.
Although all treatments are effective in managing menopausal symptoms, an increased risk of venous thromboembolism (blood clots) is a rare, but serious, known side effect. A recently issued guideline from the National Institute for Health and Care Excellence (NICE) stressed that research results from studies trying to estimate the risk of developing blood clots as a result of HRT are still not clear, and that findings to date were not a reliable basis for decision-making by doctors or patients.
The Nottingham study aimed to provide clarity on the subject by identifying and comparing venous thromboembolism risks for all forms of HRT treatment used in the UK.
The study used data from the two largest UK primary care databases (QResearch and CPRD), which contain patient records from more than 2,000 English GP practices and associated hospital records over an 18-year period (1998-2017) to investigate real-life use and risks of blood clots for all types of HRT treatments.
The researchers compared the treatment prescription records of all women who developed blood clots with those for a group of women who did not. To ensure that the results properly reflected the effects of the different therapies, the study took into account other relevant health conditions and patient characteristics, which might have affected the risk of developing blood clots.
It found that women taking HRT tablets were up to two times more likely to be at risk/had a 70 per cent risk compared to other forms of HRT.
For tablet treatments, the risk was found to differ for two types of oestrogens. Both for single and combined hormone treatments, the risk of blood clots was 15 per cent higher for the treatments containing oestrogen manufactured from horse urine than for the synthetic oestradiol.
Low risk for other forms of HRT
However, women who were using HRT in patch, gel or cream form were not found to be at risk, even at higher doses.
The results of the study could also be helpful to agencies such as NICE in the development of new best-practice guidelines.
Dr Yana Vinogradova, of the University’s School of Medicine, undertook the research. The team also included Professors Julia Hippisley-Cox and Carol Coupland.
Dr Vinogradova says: “Our study has shown that, for oral treatments, different tablets are associated with different risks of developing blood clots, depending on the active components. It has also confirmed that risks of thrombosis for patients using HRT treatments other than tablets (patches or gels) is very low.
"This lower risk has been known for more than ten years and – although patches or gels may not be acceptable in some circumstances – it was surprising to find that only 20 per cent of HRT prescriptions to date have been for non-oral treatments.
"Our findings are particularly important information for women, who require HRT treatment and are already at increased risk of developing blood clots.”
— Ends —
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email firstname.lastname@example.org or see the Globelynx website for how to register for this service.
For up to the minute media alerts, follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named both Sports and International University of the Year in the 2019 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017 and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer, proud of our Athena SWAN silver award, and a key industry partner- locally and globally.